Literature DB >> 3489782

A unique antigen on mature B cells defined by a monoclonal antibody.

M P Link, J Bindl, T C Meeker, C Carswell, C A Doss, R A Warnke, R Levy.   

Abstract

A novel 42,000 dalton antigen (MB-1) expressed by mature human B cells in blood and tonsil was identified and characterized by utilizing a hybridoma monoclonal antibody. A comparison of MB-1 with other known B cell antigens suggests that the MB-1 antigen has not been previously identified. From one-and two-color immunofluorescence studies, it appears that the MB-1 antigen is found on all normal immunoglobulin (Ig)-expressing cells, but not on T cells, thymocytes, granulocytes, or platelets. Studies of malignant B cell tumors reveal that the antigen is expressed by virtually all Ig-expressing B cell tumors but only 10% of SIg- B-lineage leukemias. Data from these studies suggest that the MB-1 antigen is expressed late in B cell ontogeny before the expression of SIg.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489782

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Authors:  Daniel S Pereira; Claudia I Guevara; Liqing Jin; Nathan Mbong; Alla Verlinsky; Ssucheng J Hsu; Hector Aviña; Sher Karki; Joseph D Abad; Peng Yang; Sung-Ju Moon; Faisal Malik; Michael Y Choi; Zili An; Kendall Morrison; Pia M Challita-Eid; Fernando Doñate; Ingrid B J Joseph; Thomas J Kipps; John E Dick; David R Stover
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

Review 2.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

Review 3.  Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.

Authors:  L J Picker; L M Weiss; L J Medeiros; G S Wood; R A Warnke
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

Review 4.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

6.  Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Authors:  Violetta V Leshchenko; Pei-Yu Kuo; Rita Shaknovich; David T Yang; Tobias Gellen; Adam Petrich; Yiting Yu; Yvonne Remache; Marc A Weniger; Sarwish Rafiq; K Stephen Suh; Andre Goy; Wyndham Wilson; Amit Verma; Ira Braunschweig; Natarajan Muthusamy; Brad S Kahl; John C Byrd; Adrian Wiestner; Ari Melnick; Samir Parekh
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

7.  Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Authors:  Sarwish Rafiq; Anthony Siadak; Jonathan P Butchar; Carolyn Cheney; Gerard Lozanski; Naduparambil K Jacob; Rosa Lapalombella; Jackie McGourty; Meghan Moledor; Richard Lowe; Ben Setter; Jeffrey Jones; Joseph M Flynn; Leslie Andritsos; Steven Devine; Xiaokui Mo; David Jarjoura; Susheela Tridandapani; Paul Algate; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

8.  Immunophenotypic profile of CNS lymphoma: a review of eighteen cases.

Authors:  R Bashir; A Freedman; N Harris; K Bain; L Nadler; F Hochberg
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

9.  Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient.

Authors:  K F Koral; K R Zasadny; F M Swailem; S F Buchbinder; I R Francis; M S Kaminski; R L Wahl
Journal:  Eur J Nucl Med       Date:  1991

10.  Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Authors:  Xiaobin Zhao; Rosa Lapalombella; Trupti Joshi; Carolyn Cheney; Aruna Gowda; Martha S Hayden-Ledbetter; Peter R Baum; Thomas S Lin; David Jarjoura; Amy Lehman; Donna Kussewitt; Robert J Lee; Michael A Caligiuri; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.